Prevalence of hepatitis D virus infection in Central Italy has remained stable across the last 2 decades with dominance of subgenotypes 1 and characterized by elevated viral replication
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved..
OBJECTIVES: Here we investigate Hepatitis D virus (HDV)-prevalence in Italy and its fluctuations over time and we provide an extensive characterization of HDV-infected patients.
METHODS: The rate of HDV seroprevalence and HDV chronicity was assessed in 1579 hepatitis B surface antigen (HBsAg)+ patients collected from 2005 to 2022 in Central Italy.
RESULTS: In total, 45.3% of HBsAg+ patients received HDV screening with an increasing temporal trend: 15.6% (2005-2010), 45.0% (2011-2014), 49.4% (2015-2018), 71.8% (2019-2022). By multivariable model, factors correlated with the lack of HDV screening were alanine-aminotransferase (ALT) less than two times of upper limit of normality (<2ULN) and previous time windows (P <0.002). Furthermore, 13.4% of HDV-screened patients resulted anti-HDV+ with a stable temporal trend. Among them, 80.8% had detectable HDV-ribonucleic acid (RNA) (median [IQR]:4.6 [3.6-5.6] log copies/ml) with altered ALT in 89.3% (median [IQR]:92 [62-177] U/L). Anti-HDV+ patients from Eastern/South-eastern Europe were younger than Italians (44 [37-54] vs 53 [47-62] years, P <0.0001), less frequently nucleos(t)ide analogs (NUC)-treated (58.5% vs 80%, P = 0.026) with higher HDV-RNA (4.8 [3.6-5.8] vs 3.9 [1.4-4.9] log copies/ml, P = 0.016) and HBsAg (9461 [4159-24,532] vs 4447 [737-13,336] IU/ml, P = 0.032). Phylogenetic analysis revealed the circulation of HDV subgenotype 1e (47.4%) and -1c (52.6%). Notably, subgenotype 1e correlated with higher ALT than 1c (168 [89-190] vs 58 [54-88] U/l, P = 0.015) despite comparable HDV-RNA.
CONCLUSIONS: HDV-screening awareness is increasing over time even if some gaps persist to achieve HDV screening in all HBsAg+ patients. HDV prevalence in tertiary care centers tend to scarcely decline in native/non-native patients. Detection of subgenotypes, triggering variable inflammatory stimuli, supports the need to expand HDV molecular characterization.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 2023 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:138 |
|---|---|
| Enthalten in: |
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases - 138(2023) vom: 15. Jan., Seite 1-9 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
63231-63-0 |
|---|
| Anmerkungen: |
Date Completed 21.12.2023 Date Revised 21.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ijid.2023.11.005 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364362987 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364362987 | ||
| 003 | DE-627 | ||
| 005 | 20231227135352.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijid.2023.11.005 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1234.xml |
| 035 | |a (DE-627)NLM364362987 | ||
| 035 | |a (NLM)37944585 | ||
| 035 | |a (PII)S1201-9712(23)00766-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Salpini, Romina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prevalence of hepatitis D virus infection in Central Italy has remained stable across the last 2 decades with dominance of subgenotypes 1 and characterized by elevated viral replication |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.12.2023 | ||
| 500 | |a Date Revised 21.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a OBJECTIVES: Here we investigate Hepatitis D virus (HDV)-prevalence in Italy and its fluctuations over time and we provide an extensive characterization of HDV-infected patients | ||
| 520 | |a METHODS: The rate of HDV seroprevalence and HDV chronicity was assessed in 1579 hepatitis B surface antigen (HBsAg)+ patients collected from 2005 to 2022 in Central Italy | ||
| 520 | |a RESULTS: In total, 45.3% of HBsAg+ patients received HDV screening with an increasing temporal trend: 15.6% (2005-2010), 45.0% (2011-2014), 49.4% (2015-2018), 71.8% (2019-2022). By multivariable model, factors correlated with the lack of HDV screening were alanine-aminotransferase (ALT) less than two times of upper limit of normality (<2ULN) and previous time windows (P <0.002). Furthermore, 13.4% of HDV-screened patients resulted anti-HDV+ with a stable temporal trend. Among them, 80.8% had detectable HDV-ribonucleic acid (RNA) (median [IQR]:4.6 [3.6-5.6] log copies/ml) with altered ALT in 89.3% (median [IQR]:92 [62-177] U/L). Anti-HDV+ patients from Eastern/South-eastern Europe were younger than Italians (44 [37-54] vs 53 [47-62] years, P <0.0001), less frequently nucleos(t)ide analogs (NUC)-treated (58.5% vs 80%, P = 0.026) with higher HDV-RNA (4.8 [3.6-5.8] vs 3.9 [1.4-4.9] log copies/ml, P = 0.016) and HBsAg (9461 [4159-24,532] vs 4447 [737-13,336] IU/ml, P = 0.032). Phylogenetic analysis revealed the circulation of HDV subgenotype 1e (47.4%) and -1c (52.6%). Notably, subgenotype 1e correlated with higher ALT than 1c (168 [89-190] vs 58 [54-88] U/l, P = 0.015) despite comparable HDV-RNA | ||
| 520 | |a CONCLUSIONS: HDV-screening awareness is increasing over time even if some gaps persist to achieve HDV screening in all HBsAg+ patients. HDV prevalence in tertiary care centers tend to scarcely decline in native/non-native patients. Detection of subgenotypes, triggering variable inflammatory stimuli, supports the need to expand HDV molecular characterization | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a HDV chronic infection | |
| 650 | 4 | |a HDV prevalence | |
| 650 | 4 | |a HDV-RNA quantification | |
| 650 | 4 | |a Hepatitis B virus | |
| 650 | 4 | |a Hepatitis D virus | |
| 650 | 7 | |a Hepatitis B Surface Antigens |2 NLM | |
| 650 | 7 | |a RNA |2 NLM | |
| 650 | 7 | |a 63231-63-0 |2 NLM | |
| 700 | 1 | |a Piermatteo, Lorenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Torre, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a D'Anna, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Khan, Sohaib |e verfasserin |4 aut | |
| 700 | 1 | |a Duca, Leonardo |e verfasserin |4 aut | |
| 700 | 1 | |a Bertoli, Ada |e verfasserin |4 aut | |
| 700 | 1 | |a La Frazia, Simone |e verfasserin |4 aut | |
| 700 | 1 | |a Malagnino, Vincenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Teti, Elisabetta |e verfasserin |4 aut | |
| 700 | 1 | |a Iannetta, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Paba, Pierpaolo |e verfasserin |4 aut | |
| 700 | 1 | |a Ciotti, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Lenci, Ilaria |e verfasserin |4 aut | |
| 700 | 1 | |a Francioso, Simona |e verfasserin |4 aut | |
| 700 | 1 | |a Paquazzi, Caterina |e verfasserin |4 aut | |
| 700 | 1 | |a Lichtner, Miriam |e verfasserin |4 aut | |
| 700 | 1 | |a Mastroianni, Claudio |e verfasserin |4 aut | |
| 700 | 1 | |a Santopaolo, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a De Sanctis, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Pellicelli, Adriano |e verfasserin |4 aut | |
| 700 | 1 | |a Galati, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Moretti, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Casinelli, Katia |e verfasserin |4 aut | |
| 700 | 1 | |a Caterini, Luciano |e verfasserin |4 aut | |
| 700 | 1 | |a Iapadre, Nerio |e verfasserin |4 aut | |
| 700 | 1 | |a Parruti, Giustino |e verfasserin |4 aut | |
| 700 | 1 | |a Vecchiet, Iacopo |e verfasserin |4 aut | |
| 700 | 1 | |a Paoloni, Maurizio |e verfasserin |4 aut | |
| 700 | 1 | |a Marignani, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Ceccherini-Silberstein, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Baiocchi, Leonardo |e verfasserin |4 aut | |
| 700 | 1 | |a Grelli, Sandro |e verfasserin |4 aut | |
| 700 | 1 | |a Sarmati, Loredana |e verfasserin |4 aut | |
| 700 | 1 | |a Svicher, Valentina |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases |d 1998 |g 138(2023) vom: 15. Jan., Seite 1-9 |w (DE-627)NLM094730857 |x 1878-3511 |7 nnns |
| 773 | 1 | 8 | |g volume:138 |g year:2023 |g day:15 |g month:01 |g pages:1-9 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijid.2023.11.005 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 138 |j 2023 |b 15 |c 01 |h 1-9 | ||